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GIT   - Gastro Intestinal Tract 
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ABSTRACT 
Inflammatory Bowel disease(IBD) is a generic term used to describe a group of 
chronic relapsing inflammatory disorders of the gastrointestinal tract, of which 
Crohn's disease (CD) and ulcerative colitis (UC) are the most common.Disease 
related knowledge plays a vital role in facilitating patient’s acceptance of their 
diagnosis and compliance with active participation in the treatment of inflammatory 
bowel disease (IBD. The aim of this study was to identify the disease specific 
knowledge in IBD patients and to improve their health related quality of life. The 
knowledge assessment was done by CCKNOW and QoL was measured by SIBDQ. 
Among 74 patients, equal number of males and females were enrolled(37 each). 
Majority of the patients were in the age group of 20-40. The distribution of UC and 
CD in the study population was 36 (48.6%) were UC patients and 38(51.4%) were 
CD patients. relatives of  23 patients were having IBD. The mean CCKNOW score 
were found to be increased in the revisit period from baseline visit (p<.001). The 
mean score of female patients were found to be more than that of males. The 
association between different domain of SIBDQ with demographic charecters were 
analysed. It was observed that age and past history found that significant relation 
with bowel domain (p<0.05). The Patients were provided with the patient 
information leaflet and then the knowledge and Qol were shown considerable 
difference in the scores. The study suggests that patient education program is 
beneficial for the patients for improving their knowledge regarding the disease. 
There is no association between the knowledge and health related quality if life in 
IBD patients. 
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INTRODUCTION 
 Inflammatory bowel disease (IBD),is a chronic disease used to describe disorders 
that involve chronic inflammation of the digestive tract. There are two forms of IBD, 
Crohn’s Disease(CD) and Ulcerative Colitis(UC), in which crohn’s disease means the 
inflammation in the lining of the digestive tract, which often spreads deep into affected 
tissue. It is the transmural inflammation which affect any part of GIT from mouth to 
anus, most commonly in the end of small intestine may appear as patches. Ulcerative 
Colitis is the condition in which the entire colon is affected as a continuous pattern, 
occurs in innermost lining of the intestine.  IBD can be debilitating and sometimes leads 
to life threatening complication1. 
 
ETIOLOGY 
 The specific etiology of IBD is unknown. A common hypothesis for the cause of 
IBD is that, it is the result of an unregulated intestinal immune response to environmental 
and bacterial triggers, probably in a host susceptible to genetic invasion.This response 
leads to the uncontrolled inflammation that causes damage to the gastrointestinal tract, 
resulting in symptoms2 of homeostatic conditions, the innate and the adaptive immune 
systemsare balanced in complex interactions with intestinal microbes. In IBD, 
thishomeostasis is disrupted and uncontrolled intestinal inflammation is developed3,4. 
 
EPIDEMIOLOGY 
 The clinical spectrum of inflammatory bowel disease (IBD) is very wide and it 
may lead to life-threatening severe illness. Although the incidence of IBD is low, ranging 
from 2–15 per 100,000 for  UC and 0.1–14 per 100,000 for CD,  the economic costs to 
the patient and the state are high. IBD such as a chronic disorder, typically affect people 
during their younger age as well as the earning period of the life time which may require 
expensive medical and surgicalinterventions during the course of the disease. The onset 
in early adult life, the chronic nature of the disease, the need for a visiting clinician, 
laboratory tests, diagnostic procedures, hospitalisation and surgery all result in high costs 
for IBD patients with UC and CD. IBD also has significant adverse effects on the quality 
of life of patients suffering from it. The level of knowledge of IBD and quality of life are 
strongly interrelated, and a lower level of disease-related knowledge leads to more severe 
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impairment of the quality of life. Although some previous studies have shown that 
patient knowledge has no effect on Health Related Quality of Life (HRQOL), currently, 
there is evidence supporting the fact that the higher the level of disease-related 
knowledge, the better the HRQOL in IBD. Chronic diseases such as IBD require patient 
education in order to achieve adequate control and prevent adverse health 
outcomes5.Disease-specific information is increasingly being recognized as important for 
patients as it improves compliance with therapy and satisfaction with their overall care6,7.  
 
CLINICAL FEATURES OF IBD PATIENTS 
 Symptoms may vary depending on the severity of inflammation and its 
occurrence. Symptoms may range from mild to severe and  patients were likely to have 
periods of active illness followed by periods of remission. Signs and symptoms are 
common to both Crohn’s disease and Ulcerative colitis. 
• Diarrhea 
• Fever and fatigue 
• Abdominal pain and cramping 
• Blood in stool 
• Reduced appetite 
• Unintended weight loss 
 
RISK FACTORS 
• Age 
• Race 
• Ethnicity 
• Family history 
• Cigarette smoking 
• NSAIDS 
 
COMPLICATION 
• Colon Cancer 
• Skin,eye joint infection 
• Medication side effects 
• Primary sclerosing cholangitis 
Introduction 
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• Blood clots 
• Bowel obstruction 
• Malnutrition  
• Ulcers, fistulas 
• Anal fissures9.  
 
PATHOPHISIOLOGY 
 The most accepted hypothesis of IBD pathogenesis is that complex interactions 
between genetics, environmental factors, and the host immune system lead to aberrant 
immune responses and chronic intestinal inflammation. The human gut harbors a 
complex and abundant aggregation of microbes, collectively referred to as the gut 
microbiota. The gut microbiota has physiological functions associated with nutrition, the 
immune system, and defense of the host. Recent advances in next-generation sequencing 
technology have identified alteration of the composition and function of the gut 
microbiota, which is referred to as dysbiosis, in IBD. Clinical and experimental data 
suggest dysbiosis may play a pivotal role in the pathogenesis of IBD. This review is 
focused on the physiological function of the gut microbiota and the association between 
the gut microbiota and pathogenesis in IBD. In addition, we review the therapeutic 
options for manipulating the altered gut microbiota, such as probiotics and fecal 
microbiota transplantation. The gut microbiota in healthy individuals is known to 
provide a number of health benefits to the host, relating to pathogen protection, nutrition, 
metabolism, and the immune system. 10,11,12 
 
 Immunopathogenesis of IBD: A dysregulated mucosal immune response is the 
central driver of IBD and is characterized by an altered innate immune system along with 
activated effector T-cells, an increased presence of B-cells and antibody production, as 
well as an increased production of pro-inflammatory mediators. Key innate and adaptive 
immune cells involved in IBD pathogenesis and cytokines produced by the various cell 
subsets in the affected mucosa are shown. The inappropriate activation and maintenance 
of inflammatory responses driven by cytokines and lack of control by reduced regulatory 
mechanisms and anti-inflammatory cytokines such as IL-10 and TGF-b lead to chronic 
intestinal inflammation. Furthermore, the inflamed intestine shows an increased 
expression of MAdCAM-1 leading to increased recruitment of gut-specific T-cells to the 
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LP and perpetuates the cycle of inflammation leading to chronic tissue injury and 
epithelial damage.13 
 
 
 
KNOWLEDGE ASSESSMENT 
 Disease-specific information is increasingly beingrecognized as important for 
patients as it improvescompliance with therapy and satisfaction with theiroverall care.As 
can thus be expected, patients with a perceivedlack of disease-related information have 
poorerhealth-related quality of life than their peers, manifestedby higher frequency of 
disease-related worries andconcerns in this group Previousstudies have shown that 
patients who receive informationrelated to their disease are less anxious, more 
compliant,and more satisfied with their treatment and havea reduced number of 
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physician visits and lower patient cost.Appropriate knowledge and information enable 
for better quality of life in patients.6 
 
QUALITY OF LIFE 
 HRQOL is generally defined as a multidimensional concept that incorporates the  
physical, emotional, and social features of health perception and health functioning. The 
diagnosis of a chronic medical disorder increases stress levels and introduces difficult 
changes, which, in turn, can alter HRQOL. For patients with IBD, such stressors may 
include abdominal discomfort, rectal bleeding, diarrhea, fecal urgency, impaired 
appetite, weight loss, and need for long-term (immunosuppressant) medication use, 
hospitalization, or surgery, among others. Thus, as with patients with other chronic 
diseases, it is not surprising that patients with IBD have poorer HRQOL compared to 
healthy controls. 
 
 Managing IBD poses challenges for the health-related quality of life (HRQoL) of 
affected youth. HRQoL is a multidimensional construct representing one’s subjective 
assessment of the impact of one’s health on physical and psychosocial functioning. 
Youth with IBD have lower HRQoL compared with healthy peers  and poorer school-
related HRQoL than healthy or chronically ill youth. Although patients suffering from 
these conditions have a normal life expectancy, the need for long-term medication, 
frequent hospitalizations, surgeries and the relapsing nature of the disease significantly 
negatively affect their quality of life (QOL)6 
 
PATIENT EDUCATION 
 Patients with IBD are at risk for serious complications when their disease is 
poorly managed. Patient non-adherence to medical therapy contributes to suboptimal 
outcomes, but may be modified through improved education. Poorly controlled disease 
increases the risk for serious and often irreversible negative outcomes including death. 
Non-adherence to medical therapy may be associated with demographic factors such as 
gender (male) and marital status (single). Individuals may forego medical and/or surgical 
therapy due to inconvenience, costs, lack of understanding, or fear of side effects from 
therapy. Inconvenience and cost of therapy are difficult to address due to their limited 
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mutability, but fear of adverse effects from therapy and lack of understanding of 
available treatment options are factors that may be amenable to change. Education 
specific to IBD, its effects, and its management, can potentially increase patient 
adherence and improve outcomes for these patients. Current evidence suggests that many 
individuals with IBD lack the desired information about their disease. Specific areas of 
interest to IBD patients include: prevention and management of IBD symptoms, 
complications related to IBD, long term prognosis, risk of cancer and mortality, 
alternative therapies, risks from pharmacotherapy, potential new therapies, and fertility  
These information needs were identified through surveys administered to specific patient 
populations (e.g.newly diagnosed); however, to our knowledge an intensive qualitative 
study in a diverse IBD patient population specifically exploring this topic has not been 
published. This study is to determine the perceived educational needs of IBD patients 
(i.e. the information about issues that a patient desires to understand such as their disease 
process, prognosis, and therapeutic options), and to identify areas where providers 
believe patient understanding is critical. This information can be used to develop novel 
educational resources to facilitate patient adherence to therapy.7 
 
 Awareness is needed for chronic diseases like IBD to attain adequate control and 
require patient education in order to achieve adequate control and reduce harmful health 
issues. Disease based information has also a crucial role in helping patients to accept 
their health condition with an ease and to understand proper behavioral alterations that 
are needed in order to take part in the treatment effectively and also in enhancing the 
relationship of the doctor and patient.8 
 
Need for assessing Knowledge and Quality of life  
 Disease related knowledge plays a vital role in facilitating patient’s acceptance of 
their diagnosis and compliance with active participation in the treatment of Inflammatory 
Bowel Disease (IBD).The level in knowledge of IBD and quality of life are strongly 
inter-related, and a lower level of disease related knowledge leads to more severe 
impairment in the quality of life in IBD patients. Although some previous studies have 
shown that patient knowledge has no effect on Health Related Quality of Life (HRQOL) 
but currently there is a evidence supporting the fact that the higher the level of disease-
Introduction 
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related knowledge, the better the HRQOL in IBD13. So there should be a furthermore 
advance study is essential to improve the patients’ understanding of their disease. Lack 
of knowledge and understanding about IBD may impair a patient’s ability to be an active 
participant in his/her own management. A working knowledge of their disease and its 
management is essential for patients with chronic disorders such as IBD. So a validated 
patient knowledge score for IBD has been developed and assessed, in relationship with 
HRQoL14. Additionally, disease related knowledge of IBD among patients may affect 
adherence to medications or coping skills, and hence affect HRQoL. 
 
 Chronic diseases such as IBD require patient education in order to achieve 
adequate control to prevent the adverse health outcomes.15. The patients should aware 
about the chronic nature of this disease if it is untreated or with the consequences of the 
disease when it persist. So it is very important to provide a better patient education for 
the awareness of  the disease and their do’s and dont’s..There by patient may improve 
their quality of life in a healthy way16,17,18 
 
 There have only been a few studies that have assessed disease related knowledge 
in IBD,and that have been carried out in western countries.The incidence and prevalence 
indicating that the IBD is increasing gradually and the patient's knowledge about disease 
is very less.  
 
 The purpose of this study was, to determine the difference in disease related 
knowledge and information needs according to the general characteristics of IBD 
patients, then  to improve the knowledge about the diseases and quality of life. 
Literature Review 
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LITERATURE REVIEW 
 Chouliaras G et al.,(2017) conducted a cross sectional study to assess the 
impact of disease characteristics onthe quality of life (QOL) in children with 
inflammatorybowel diseases (IBD).  The results of this study indicated that the 
disease activity is the major factor associated with low QOL in children with IBD. 
This study demonstrated that disease activity is the main correlation of quality of life 
(QOL) in children. Several factors, that increased risks for impaired QOL for children 
with IBD, were identified. So the children of younger age, the early years after the 
diagnosis and the presence of extra-intestinal manifestations were inversely related to 
IMPACTIII scores. Therefore, in children with these specific features, physicians 
should be more vigilant in order to recognize and address issues related to their QOL 
promptly17.. Soobraty A et al.,(2017)  conducted a survey on current practice of  
clinicians regarding medication non-adherence  in patients with Inflammatory Bowel 
Disease.Respondents stated forgetfulness, beliefs about necessity of medication and 
not immediately apparent benefits as the main reasons for non-adherence. Patient 
counselling on benefits and risks of medication was a commonly used 
intervention.They concluded that urgent need for further clinician education on non-
adherence and robustly tested interventions that are capable of improving adherence.19 
 
 Reghu et al.,(2017) conducted a prospective, interventional follow up study to 
evaluate clinical pharmacist’s interventions have any impact on medication adherence 
of patients having inflammatory bowel disease and to assess the awareness of patients 
about their disease and the significance of medications they use.  They concluded that 
proper education program has a good effect on patients to improve their knowledge 
level on ibd20. 
 
   Chen et al .,(2017) done a study to identify the environmental risk factors that 
are associated with IBD. Several environmental factors, such as smoking, 
appendicitis, OCPs, diet, breastfeeding, infections/ vaccinations, antibiotics, 
helminths, and childhood hygiene, have been implicated in the increased worldwide 
incidence of IBD. But  the most consistently demonstrated environmental risk factor, 
smoking, contributes only partially to disease pathogenesis (ie, most smokers do not 
Literature Review 
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have CD and most CD patients do not smoke). Thus, further studies are necessary to 
better understand the environmental determinants of IBD21. 
 
 Velonias et al (2017) done a study to analyse health related quality of life in 
older age. They resulted that Older age patients was associated with modestly higher 
SIBDQ and mental HRQoL but lower physical HRQoL. Comprehensive care of the 
older IBD patient should include assessment of factors impairing physical quality of 
life to ensure appropriate interventions22. 
 
 L.Dibley et al.,(2017) done a study to identify the research priorities for the 
nursing of inflammatory bowel disease patients. And they concluded that these 
research priorities have a good impact on the nursing of IBD patients23. 
 
 Anna catarena.,et al (2017) conducted a study to observe a relation between 
appendectomy and IBD, crohns disease. And found out that transient increased risk of 
Crohn’s disease after an appendectomy was probably explained by diagnostic bias.24 
 
 Wheat C. L. et al.,(2016) conducted a study to identify educational needs, and 
barriers and factors associated with non-adherence among inflammatory bowel 
disease (IBD) patients.Eighteen IBD patients and ten IBD providers were recruited. 
Semi-structured interviews were conducted and a qualitative framework approach 
used to identify patient educational needs, barriers to obtaining information, and 
factors associated with non-adherence with medical therapy. They concluded that 
there are several deficits in knowledge in IBD patients and they  identified factors 
associated with IBD patient comprehension, decision making, and non-adherence to 
therapy. These results can be used to develop targeted educational resources to 
improve adherence among IBD patients and they propose that patient self-
management programs are potentially effective educational interventions that warrant 
further study in IBD25. 
 
 A. A. El. Mahalli, H.M. Ali Alharthi et al.,(2016) done a study to assess the 
health related quality of life of patients with inflammatory bowel disease. They 
concluded as relapse,long duration of disease ( <5yrs),low education and young age at 
disease onset may entail increased risk for decreased HRQOL.26 
Literature Review 
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 Sasha Taleban et al.,(2016) conducted a study  to examine the correlation 
between QOL and clinical activity indices and endoscopic disease activity according 
to disease characteristics. data suggest good correlation between SCCAI and 
endoscopic disease activity in UC, particularly in left-sided disease. Poor correlations 
between HBI or SIBDQ and SES-CD appear to be consistent across different disease 
phenotypes.27 
 
 Hou JK et al.,(2015) conducted a prospective study to evaluate the 
association between patient disease knowledge of inflammatory bowel disease (IBD) 
and health related quality of life (HRQoL) and identify patient and disease related 
predictors of patient knowledge of IBD. IBD diagnosis at a younger age in addition to 
Caucasian race and higher education were significantly associated with higher 
knowledge about IBD. However, patient knowledge of IBD was not  correlated with 
HRQoL. Further studies are required to study the effect of patient knowledge of IBD 
on other clinical outcomes.18 
 
 Zhang YZ et al.,(2014) done a study about the pathogenesis and and the risk 
factors about the disease. They found out that the key factors responsible for IBD 
include genetic components, environmental elements, microbial flora and immune 
responses. It is hard to dispute the popular belief that IBD arises from an extremely 
complex interaction among genetic and environmental elements, dysregulated 
immune responses and alterations of the microbiome, and that none of these factors 
alone is likely to cause the disease. The growing number and diversity of genetic loci 
associated with IBD provide major challenges to the investigation of how they impact 
immunity and inflammation in susceptible individuals. Future research needs to 
further clarify and integrate the effects of the microbiome and environment on the 
immune response, and it shall be essential to gain further insights into the mechanisms 
and pathways of how bacteria, viruses or even fungi can modulate innate and adaptive 
immune responses.1 
 Huppertz-Hauss et al.,(2015) conducted a study to evaluate the HRQoL in 
European patients with ulcerative colitis and Crohn’s disease,10 years after diagnosis 
Literature Review 
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(European Collaborative study group of Inflammatory Bowel Disease) compared with 
the national background population in each country and to assess possible country-
specific differences. Patients with IBD from 7 European countries were included in 
the study and done a follow-up visit 10 years after their diagnosis of IBD. They  
assessed their clinical and demographic data, including the generic HRQoL 
questionnaire short form health survey-36.They concluded that  the HRQoL was not 
reduced in the IBD cohort compared with the background populations and old age, 
female gender, current symptoms at follow-up, disablement pension, and sick leave 
during the previous year were significantly associated with a reduced HRQoL in 
patients with IBD31. 
 
 S. Lonnfors et al.,(2014) done a survey on patients with IBD to analyse the 
impact of IBD in their health related quality of  life and obtaining  a better 
understanding of the quality of care, assess to care. The result of this survey present a 
large up to date, high quality data set and this data can be used for the furthermore 
unmet needs of IBD patients for their awareness.47 
 
 Ananthakrishnan et al.,(2014) done a study to find out the various trigger 
factors for the development of IBD. This study shows that Lower plasma vitamin D is 
associated with anincreased risk of Crohn’s disease, and vitamin D supplementation 
may prevent relapse of disease.There is continuing evidence that depression and 
psychosocialstress may play a role in the pathogenesis of both CD and UC, while at 
the same time alsoincreasing risk for disease flares. There is also a growing 
understanding of the role of diet on IBD,in particular through its effect on the 
microbiome.  There is need for routine measurement of aspectrum of environmental 
exposures in prospective studies to further our understanding. 
 
 Joana Magalhaese et al.,(2014) done a study to analyze the relationship 
between clinical and sociodemographic factors and quality of life in inflammatory 
bowel disease patient. They found out that the decrease in HRQL was significantly 
related with personal perception of a lower disease impact in success and social 
Literature Review 
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relations. These factors deserve a special attention, so timely measures can be 
implemented to improve the quality of life of patients.32 
 
 J. Burisch et al(2014): in a population based study  to assess and validate the 
pattern of HRQoL in an unselected, population-based inception cohort of IBD patients 
from Eastern andWestern Europe. Medical and surgical treatment improved HRQoL 
during the first year of disease. They concluded that the majority of IBD patients in 
both Eastern and Western Europe reported a positive perception of disease-specific 
but not generic HRQoL. Biological therapy improved HRQoL in CD patients, while 
UC patients in need of surgery or biological therapy experienced lower perceptions of 
HRQoL than the rest. 
 
 Irina Blumenstein et al.,(2013) conducted a study  to assess sources of 
information and patient knowledge in Irish and German inflammatory bowel disease 
patients. they found out that  German patients obtained knowledge from a wider range 
of sources than Irish patients and few differences between German and Irish IBD 
patients, despite cultural and linguistic differences, with regard to disease related 
knowledge of IBD33. 
 
  Amitha Prasad Gumidyala et al.,(2013) done a cumulative risk model 
approach to examine cross-sectional relationships among several potential risk 
factors and HRQoL in a sample of youth with IBD using the CRM framework. They 
hypothesized that a higher number of risk factors would be associated with lower 
youth HRQoL total scores, as well as lower HRQoL scores in the physical and 
psychosocial health domains. Overall, their findings offered support for the value of 
the CRM in explaining variance in HRQoL of youth with IBD. The CRI was 
associated with all youth- and mother-reported HRQoL domains. Furthermore, 
contextual domain factors were most consistently associated with youth and maternal 
reports of HRQoL. These results show promise in supporting the value of the CRI in 
identifying potential risk factors for lower HRQoL in a cross-sectional sample34. 
 
 A. Moradkhani et al.,(2013) conducted a study on 134 patients. Individuals 
with IBD who report higher perceived stress, lower perceived social support, greater 
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number of relapses, or are female may be at increased risk for decreased HRQOL. 
Prospective studies should investigate how interventions addressing these factors may 
lead to improved HRQOL.28 
 
 C.P. Selinger et al.,(2012) conducted a study to identify predictors of anxiety 
in IBD and examine the interplay between anxiety and disease-related patient 
knowledge and The effect of anxiety on quality of life was also explored. Disease-
related knowledge was assessed using thevalidated Crohn's and Colitis Knowledge 
score (CCKnow) and disease related QOL using the short IBD questionnaire 
(SIBDQ). Anxiety anddepression were assessed with the Hospital Anxiety and 
Depression Scores. Of the 258 patients 19.4% had a potential anxiety and a further 
22.4% had a probable anxiety disorder. The study concluded that disease related 
quality of life was significantly lower in patients with anxiety and an educational 
intervention may not necessarily reduce anxiety. Further work is needed to evaluate 
the association between anxiety and knowledge and to develop targeted interventions 
that will improve knowledge and simultaneously reduce anxiety.36 
 
 Lars-Petter Jelsness-Jørgensen et al.(2012)conducted a study to assess the 
disease relatedworries and concerns among IBD patients  prospectively for one year. 
And the IBD-related worries associated with Socio demographicand clinical data. In 
addition, they evaluated the psychometric properties of the Norwegianversion of the 
RFIPC.They found out that the pattern of worries in IBD is relatively consistent over 
a period of one year. However, the level of worries, as measured with the RFIPC, 
increased successively with IBD symptoms. Their findings might indicate that the 
current IBD symptoms that are important for the level of worrying and not a history 
of serious events in the past.35 
 
 Keefer et al.(2012) done a study to develop a valid and reliable measure of 
IBD-specific Self Efficacy Scale that can be used in clinical and research contexts. 
And in their study,122 adults with a verified IBD diagnosis were participated. They 
concluded that 29-item IBD-SES has high internal consistency (r= 0.96), high test-
retest reliability (r = 0.90), and demonstrates strong construct and concurrent validity 
with established measures. The IBD-SES was a critical first step towards addressing 
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an important psychological construct that could influence treatment outcomes in 
IBD.37 
 
 Fabiana clastiglione et al (2012).,done a prospective observational study to 
evaluate risk factors for IBD related to HH in a cohort of IBD patients.We 
investigated the main surrogate markers of HH (helmintic infections and antibiotics in 
childhood; breastfeeding; family size/sibship; urban upbringing; personal and 
domestic hygiene in childhood) in UC and CD patients, in comparison with a control 
group of healthy subjects. In addition, the traditional risk factors for IBD were also 
recorded. Familial aggregation, smoking habits and appendectomy still remain the 
main risk factors associated with IBD38. 
 
 Samaraskera et al.,(2010) conducted a study on 184 patients  to analyse the 
disease related knowledge in inflammatory bowel disease which was conducted in a 
tertiary care centre in a developing country in South Asia. The aim of this study was 
to analyse the deficits in knowledge for future health education programmes. There is 
a lack of knowledge regarding colorectal cancer risk and surgical interventions. There 
was no significant difference in the knowledge scores between genders but there was 
a significant association with the educational level39. 
 
 Mikocka Walus et al.,(2008) done a observational study to compare the 
clinical outcomes in relation to psychological co-morbidity in patients with 
inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and chronic 
hepatitis C (HCV) and to assess the psychological co-morbidities that are related with 
these diseases. They concluded that there was no significant relation between the 
psychological problems at baseline and clinical outcomes so further studies needed 
for better understanding40. 
 
 Waters et al.,(2005) conducted a study on 65 patients The purpose of the 
present study was to evaluate the effects of a formalized education program on 
patients with IBD. Assessment of IBD knowledge and QOL occurred at baseline, 
immediately posteducation and eight weeks posteducation. Participants documented 
medication adherence and health care use in diaries. Patient satisfaction was assessed 
Literature Review 
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at the end of the study. The formal IBD patient education program improved 
knowledge, perceived knowledge and patient satisfaction. Positive trends toward 
greater medication adherence and lower health care use were demonstrated.. The 
current study shows that there is a great impact on education program on their 
increased quality of life.41 
 
 Kaplan, Pedersen, Andersson, et al.,(2007) done a population-based cohort 
study in Swedenand Denmark to assess the risk of developing Crohn’s disease after 
an appendectomy and they concluded that the transient increased risk of Crohn’s 
disease after an appendectomy is probably explained bydiagnostic bias.46 
 
 J. Burisch et al., (2014) done a study to assess and validate the patternof 
HRQoL in an unselected, population-based inception cohort of IBD patients from 
Eastern andWestern Europe. They found out that Medical and surgical treatment 
improved HRQoL during the first year of disease and the majority of IBD patients in 
both Eastern and Western Europe reported a positive perceptionof disease-specific but 
not generic HRQoL. They also resulted that biological therapy improved HRQoL in 
CD patients,while UC patients in need of surgery or biological therapy experienced 
lower perceptions ofHRQoL than the rest. 
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AIM AND OBJECTIVES 
AIM: 
 To study the deficits of disease specific knowledge in IBD patients and to improve 
their health related quality of life. 
 
OBJECTIVES: 
• To analyse the disease related factor associated with IBD knowledge. 
• To prepare patient information leaflet for IBD. 
• To identify the knowledge deficits and to provide interventional patient education. 
• To compare the difference in knowledge of IBD Patients. 
• To assess the association between IBD knowledge and Health Related Quality of 
Life (HRQoL). 
 
 
 
Methodology 
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METHODOLOGY 
STUDY DESIGN: 
 Aprospective observational study on knowledge assessment and quality of life 
of IBD patients. Assessment of knowledge and quality of life was done in their pre 
visit and PILS were provided inorder to make them better understanding. On their post 
visit knowledge and quality of life were re assessed and the difference were analysed. 
STUDY SITE: 
 The study was conducted at the Department of Gastroenterology, Kovai 
Medical Center and Hospital,(KMCH) at Coimbatore. 
STUDY PERIOD: 
 The study was conducted from the period from February 2018to July 2018. 
STUDY POPULATION: 
 A total of 74 IBD patients were included in this study, 
STUDY CRITERIA: 
INCLUSION CRITERIA: 
¾ Patients aged between 20 - 80 years of both genders (male and female). 
¾ Patients diagnosed with IBD 
¾ Atleast one prior outpatient clinic visit with gastroenterologist. 
 
EXCLUSION CRITERIA: 
• The patients having lack of cooperation and diagnosed mental illness. 
• Being too ill to participate. 
• Pregnant womens were excluded. 
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SOURCES OF DATA: 
  A specially designed data collection form will be utilized to collect patient’s 
demographic details, past and present medical conditions, psychological factors, 
clinical features, intestinal manifestation and all other details required for the study. 
STUDY TOOLS 
• Patient proforma 
• CCKNOW scale(for monitoring knowledge) 
• PILS 
• SIBDQ(to assess the  quality of life) 
• Patient satisfaction. 
 
STUDY PROCEDURE 
  Inflammatory bowel disease (IBD), chronic inflammatory condition of the 
gastrointestinal tract resulting in a marked decrease in health related quality of life. 
Patients with IBD often experience remission and alternating with periods of disease 
activity (relapse). Although the patient suffering fromthese conditions will have a 
deficits in disease related knowledge and there by affects their quality of life. So 
adequate knowledge about the disease may improve their quality of life. 
  Literature review; an extensive literature survey was done on different aspects 
in knowledge and quality of life of patients. The literatures supporting the study was 
collected from various journal like World journal of Gastroenterology, Journal of 
young pharma, Singapore International journal etc. 
  Ethical committee approval for conducting the study in the hospital was 
obtained from the chairman, Kovai Medical Center and Hospital, Coimbatore on 10th 
of February. 
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questionnaire. All the patients were counselled and provided with patient information 
leaflet regarding the disease. After 4-5 weeks these patients were interviewed again 
with these CCKNOW and SIBDQ questionnaire. 
KNOWLEDGE ASSESSMENT  
 Knowledge assessment was done by Crohns And Colitis Knowledge 
Assessment Score(CCKNOW). The CCKNOW scorewas selected because it has a 
valid index of high internalconsistency. It also has a high reliability that assesses 
thedisease-related knowledge of IBD patients in four specificknowledge areas with 
regard to the management of IBD.These include a general understanding of the 
disease (12questions), diet (2 questions), treatment (5 questions) andcomplications (5 
questions). One point was awarded foreach correct answer and there were no negative 
marksfor incorrect answers, with a maximum possible scoreof 24 for all questions. 
Each patient in this study was given a knowledge score in their pre visit and post visit 
of my study. 
QUALITY OF LIFE ASSESSMENT 
 TheSIBDQ uses 10 questions derived from the original 32item full 
Inflammatory Bowel Disease Questionnaireto subjectively assess the HRQoL in 
patients withIBD. The SIBDQ examines four domains: bowelsymptoms, systemic 
symptoms, emotional function,and social function. Each question is scored from 0 to7 
with a total score ranging from 10 (worst health) to70 (best health). 
STATISTICAL ANALYSIS 
 Statistical Analysis was done by using SPSS (statistical package for the social 
science) version 16. Socio demographic characteristics were compared before and 
after intervention between the knowledge scores by chi square test. The mean values 
of the scores before and after intervention and QoL were calculate by paired ttest. The 
mean scores of each domains of SIBDQ with socio demographic were assessed by 
ANOVA. 
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TABLES AND FIGURES 
Table1:Age Wise distribution of total Study Population(n=74) 
 
 
 
 Fig 1: Plot for Age wise distribution of total study population 
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Sl.No 
          
Age(yrs) 
UC (36) CD (38) 
% % 
1 20-40 17(22.9) 17(22.9) 
2 41-60 14(18.92) 14(18.92) 
3 61-80 5(6.76) 7(9.46) 
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Table 2:Gender Wise Distribution of Study Population (n=74) 
 
 
 
 
 
 
 
 
 
 
Fig 2: Plot for Gender wise distribution of study population  
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           UC (36) CD (38) 
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1 Male 21(28.38)  
16(21.62) 
 
2 Female 15(21.62) 22(29.73) 
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Table 3:Clinical Features of Study Population(n=74) 
 
 
 
 
 
 
  
 
Fig 3:  Plot for Clinical features of study population 
 
 
 
 
Table 4: Past history Of Patients (n=74) 
27.03
3
0
5
10
15
20
25
30
35
40
abdomin
Pe
rc
en
ta
ge
 %
Sl.No Complaints UC(n=36) CD (n=38) 
% % 
1. Abdominal pain 20(27.03%) 25(33.78%) 
2. Loose stool 10(13.51%) 6(8.11%) 
3. Weight loss 1(1.35%) 5(6.75%) 
4. Blood in stool 5(6.76%) 2(2.70%) 
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Fig 4:: Plot for  Past history of Patients 
 
 
 
Table:5  Distribution of surgery patients among study population( n=74) 
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1. NIL 20(27.03) 19(25.68) 
2. DM 5(6.76) 6(8.11) 
3. HTN 3(4.05) 0(0) 
4. INTESTINAL DISORDER 0(0) 1(1.35) 
5 IBD 2(2.7) 7(9.46) 
6 OTHER 6(8.11) 5(6.76) 
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Fig5 Distribution of surgery patients among study population 
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1 YES 9(12.16%) 17(16.49%) 
2 NO 27(22.97%) 21(28.38%) 
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Table: 6 Distribution of Appendictitis Patients( n=74) 
 
 
 
 
 
 
 
 
Fig 6: Distribution of Appendictitis Patients 
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1. YES 6(8.11%) 6(8.11%) 
2 NO 30(40.54%) 32(43.24) 
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Table:7  Type of food habits among total study population n=74 
 
Sl.No 
 
Food Habits 
 
UC (36) CD (38) 
% % 
1. Vegetrian 5(6.76) 7(9.46) 
2. Non Vegetarian 31(41.89) 3141.89 
 
 
 
 
 
 
 
Fig 7:Type of food habits among total study population n=74 
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Table: 8 Psychological factors among total study population n=74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 8:Psychological factors among total study population n=74 
 
 
  
44.5
4.05
48.65
2.7
0
10
20
30
40
50
60
Stress Emotion
Pe
rc
en
ta
ge
 %
Psychological factors
UC
CD
Sl.No 
 
PHYCHOFACTORS 
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 % % 
1 STRESS 33(44.5) 36(48.65) 
2 EMOTION 3(4.05) 2(2.70) 
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Table:9 Life style habits among study population=74 
 
Sl.No Life style 
habits 
UC (36) CD (38) 
% % 
1 Coffee 26(35.14) (33.78) 
2 Tea 9(12.16) 13(17.57) 
3 Alcohol 1(1.35) 0 
 
 
 
 
 
 
Fig 9: Life style habits among study population=74 
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Table 10. Newly diagnosed patients among study population(n=74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 10: Plot for Newly diagnosed patients among stusy population (n=74) 
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Table 11: Duration of IBD among study population (n=74) 
 
 
 
 
 
 
 
 
 
Fig 11: Plot for Duration of IBD among study population(n=74) 
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Tabk 12: Hospitalisation among total study population 
 
 
 
 
 
 
 
 
Fig 12: Plot for Hospitalisation among total study population 
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Table 13: Clinical Manifestation among the study population (n=74) 
 
 
 
 
 
 
 
 
 
Fig 13:Clinical Manifestation among the study population (n=74) 
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1 Arthralgia 7(9.465) 9(2.16%) 
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3 Skin lesion 0 1(1.35%) 
4. Hepato biliary 0 1(1.35%) 
5. Nil 26(35.14%) 23(31.08%) 
     Tables and figures 
Department of Pharmacy Practice 34 
 
 
 
Table 14:Localisation of the inflammation among the study population (n=74) 
 
 
 
 
 
 
 
 
 
 
 
Fig 14 :Localisation of the inflammation among the study population (n=74) 
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Table 15: Relapsed patient among study population 
 
 
 
 
 
 
 
 
Fig 15: Relapsed patient among study population 
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Table 16: Family History among study population 
 
 
 
 
 
 
 
 
 
Fig 16: Family History among study population 
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PERCENTAGE OF CORRECT ANSWERS FOR CCKNOW QUESTIONNAIRE 
BEFORE AND AFTER VISIT 
 
 
Fig.17: Percentage of correct answers for CCKNOW questionnaire before and after 
visit 
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Table 17: Demographic features and their association with patient knowledge   
(CCKNOW score) 
Variable No of 
patients 
% Mean± SD p value 
GENDER 
Male 
Female  
 
37 
37 
 
50% 
50% 
 
2.97±0.49 
0.2 
AGE 
20-40 
41-60 
61-80 
 
34 
28 
12 
 
45.9% 
37.8% 
16.2% 
 
3.17±0.45 
2.85±0.35 
3.08±0.51 
0.18 
EDUCATION 
STATUS 
Primary 
Secondary 
Higher 
 
 
34 
30 
10 
 
 
 
45% 
40% 
13% 
 
 
16.79±1.70 
16.11±2.58 
15.06±1.56 
 
 
0.01 
EMPLOYEMENT 
STATUS 
Employed 
Unemployed 
Student 
 
 
29 
31 
14 
 
 
39% 
41% 
18% 
 
 
15.76±0.0123 
14.76±1.1232 
14.23±1.56 
 
 
0.06 
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Table 18: Demographic features and their association with patient knowledge    
(CCKNOW score) 
Disease characteristics No of 
patients 
N=74 
Percentages mean±SD p 
value 
Type of IBD 
UC 
CD 
 
37 
37 
 
50% 
50% 
 
16.63±1.64 
15.73±2.50 
 
 
0.04 
Duration of IBD(mnths) 
1-6  
7-12 
>1 yr 
 
32 
2 
27 
 
43.2% 
2.7% 
36.5% 
 
16.25±1.70 
14.50±2.12 
16.25±2.58 
 
 
0.09 
IBD related surgeries 
Yes  
No  
 
35.1% 
64.9% 
 
35.1% 
64.9% 
 
3.2±0.42 
2.91±0.40 
 
0.1 
Intestinal manifestations 
Arthralgia 
Bache ache 
Hepatobiliary 
Skin lesion  
Nil   
 
16 
7 
1 
1 
49 
 
21.6% 
9.5% 
1.4% 
1.4% 
66.2% 
 
3.12±0.50 
3.14±0.69 
2.00 
3.00 
 
 
0.11 
Location 
UC Proctitis 
Left colon 
Pancolitis 
CD ileal  
Ileocolonic 
Colonic  
 
12 
6 
16 
12 
20 
8 
 
16.2% 
8.1% 
21.6% 
16.2% 
27.2% 
10.8% 
 
16.50±1.50 
17.83±1.32 
16.00±1.46 
15.91±1.97 
15.75±2.48 
16.25±3.61 
 
 
 
0.442 
IBD related hospitalization 
Yes 
No 
>1 
 
6 
38 
30 
 
8.1% 
51.4% 
40.5% 
 
16.50±2.07 
16.23±2.12 
16.25±2.58 
 
 
0.09 
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Table 19: COMPARSON OF SIBDQ SCORES OF IBD PATIENTS BEFORE AND 
AFTER INTERVENTION 
 
Table 20: COMPARISON OF DOMAINS OF SIBDQ SCORES BEFORE AND 
AFTER INTERVENTION 
 
 
Sl.No 
 
 
Components 
 
Before 
intervention 
 
 
After 
intervention 
 
 
p value 
Mean±SD Mean±SD 
1 Systemic 
 
9.5946±2.0062 12.3378±0.81555 .000 
2 Social 9.3514±2.3433 12.1892±0.8707 .000 
3 Bowel 14.3919±3.0512 18.5000±1.3059 .000 
4 Emotional 14.4865±3.0576 15.2055±1.09238 .068 
Sl.No Components Before 
intervention 
Mean±SD 
After 
intervention 
Mean±SD 
Before-
After 
Intervention 
p value 
1 Feeling of fatigue 1.0135±0.1162 1.0000±.0000 .321 
2 Cancellation of social 
engagement  
5.3514±6.08711 6.1081±0.4844 .288 
3 Difficulties in doing sports 
activities 
4.6892±1.18120 6.0811±.46099 0.02 
4 Paining in the abdomen 4.7568±1.20286 6.0946±.55317 0.04 
5 Feeling depressed 4.8919±1.1173 6.0946±0.5531 0.03 
6 Difficulties in passing gas 1.3919±0.4915 1.0270±0.1632 .000 
7 Problems on getting weight 1.9595±.19857 1.9189±.27482 .260 
8 Feeling relaxed 4.7027±1.22452 2.8514±.90179 .000 
9 Feels to go to bathroom  4.8243±1.06447 6.2432±.67865 .000 
10 Feeling angry 4.8919±1.11733 6.2432±.61512 .000 
 
11 Total BDI score 46.9324േ9.021 58.2703±3.0757 .000 
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Table 21: COMPARISON OF DEMOGRAPHIC CHARACTERISTICS WITH SIBDQ DOMAINS  
  CHARACTERISTICS n=74 SYSTEMIC SOCIAL BOWEL EMOTIONAL 
Mean±SD p value Mean±SD   p value Mean±SD p value Mean±SD p value 
Gender  
 
Male 37 12.32±0.93 .480 12.13±1.08 .597 18.56±1.51 .659 15.27±1.10 .527 
Female 37 12.405±0.68 12.24±0.59 18.43±0.9586 15.10±1.219 
Age 
 
 
20-40 34 12.32 ± .87 .746 12.00±0.49 .228 18.32±1.47 .0569 15.38±1.1 .350 
41-60 28 12.28±0.76 12.35±1.19 18.64±1.22 15.07±1.083 
61-80 12 12.50±0.79 12,33±0.77 18.68±0.98 14.91±1.09 
Educational 
status 
 
Primary 13 12.21±0.85 .707 11.94±1.1772 .653 18.43±1.3 .761 15.42±.9015 .664 
Secondary 27 12.48±0.653 12.36±0.70 18.36±1.25 15.04±1.09 
Higher 21 12.23±0.99 12.19±0.81 18.52±1.0 15.±1.060 
Past History 
 
 
 
 
DM 11 12.00±0.447 .635 12.0±0.000 .495 18.90±0.83 .56 15.36±1.120 .727 
HT 3 12.33±0.5773 13.00±1.000 18.66±.57 15.66±0.57735 
Intestinal 
Disorder 
1     
IBD 9 12.44±0.52 12.44±0.88 17.55±1.740 15.2±0.971 
Other  11 12.18±1.40 12.00±0.89 17.90±1.77 14.72±1.79 
 
Surgery 
Yes 26 12.42±0.71 .512 12.0±0.426 .393 18.41±1.24 .712 15.25±1.05 .124 
No 48 12.37±0.83 12.12±0.95 18.45±1.41 15.33 ±1.05 
 
Appendictitis 
Yes 12 12.166±0.71 .04 12.00±.426 .415 18.41±1.24 .811 15.25±1.0 .835 
No 62 12.37±0.83 12.22±0.93 18.51±1.32 15.17±1.10 
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Charecteristics n=74 Syste
mic 
Social Bowel Emotional      
  Mean
±SD 
p value Mean±SD p value Mean
±SD 
p value Mean±
SD 
p value . 
 
.947 Tea 22 12.63±0.65 12.40±0.734 18.77±0.8 15.13±0.88 
Food habits Veg 12 12.50±0.52 .456 12.58±0.9 .087 18.50±1.24 .001 14.9167±1.08  
.349 Non veg 62 12.30±0.860  12.11±0.85  18.5000±1.3  15.24±1.09 
Family history First 
relative 
Second 
relative 
Nil 
22 
1 
51 
12.09±0.61 
13.00 
12.33±0.81 
.189 12.04±1.09 .082 18.50 ±1.40 .930 15.45±0.96 .0246 
Psycho factors Stress 
emotion 
69 
5 
12.31±0.83 
12.60±0.54 
.460 12.20±0.90 .618 18.50±1.21 .217 15.15±1.10 .0388 
Duration of 
IBD 
1-6 
mnths 
7-12 
mnths 
>1 yr 
nil 
32 
2 
27 
13 
12.37±0.70 
12.50±0.70 
12.37±0.62 
12.15±0.81 
.843 12.37±0.70 
 
.094 18.34±0.6 .871 13.45±1.0 .232 
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Table 22: MEAN AND STD DEVIATION OF PATIENT SATISFACTION SCORE 
 
Descriptive Statistics 
 N Minimum Maximum Mean Std. Deviation
psq1 74 1.00 4.00 1.7027 .59056 
psq2 74 1.00 4.00 2.3378 .60312 
psq3 74 1.00 4.00 2.2568 .52501 
psq4 74 4.00 5.00 4.3243 .47132 
psq5 74 2.00 4.00 2.7162 .74980 
psq6 74 1.00 4.00 2.2973 .71634 
psq7 74 2.00 5.00 3.0405 .86704 
psq8 74 1.00 5.00 3.5135 1.01013 
psq9 74 1.00 2.00 1.2973 .46019 
psq10 74 2.00 5.00 3.4595 .62349 
psq11 74 2.00 5.00 2.6757 .68463 
psq12 74 2.00 5.00 3.2027 .85975 
psq13 74 2.00 4.00 3.2027 .79346 
psq14 74 2.00 5.00 4.2973 .71634 
psq15 74 2.00 5.00 3.3784 .80585 
psq16 74 1.00 4.00 2.2432 .80768 
psq17 74 2.00 5.00 3.8378 .57403 
psq18 74 1.00 4.00 2.8378 .90701 
 
Results And Discussion 
 
Department of Pharmacy Practice 44 
 
RESULTS AND DISCUSSION 
 Inflammatory Bowel Disease is characterized as a chronic disorder that are 
related to unknown aetiology. Disease-related knowledge plays a critical role in 
facilitating patients’ acceptance of their diagnosis and compliance with active 
participation in the treatment of inflammatory bowel disease (IBD). This prospective 
observational study was aimed to measure the deficits in knowledge and their quality 
of life 
I. DEMOGRAPHIC FEATURES 
 A total of 74 patients were enrolled in the study. There were equal number of 
males and females,37 patients. The mean age of this study participants was 
1.7027±.73521, 
a) Age: Out of which 36 (48.6%) were UC patients and 38(51.4%) were CD 
patients. There were 34  patients falls within the age group 20-40(45.9%). The 
type of UC and CD distribution in this age group is equally 17(22.97%). And 
28 patients falls within the age group 41-60(37.8%). The type of UC and CD 
distribution in this age group is  14(18.92%). There were 12 patients in the age 
group 61-80 and was 6.76% and 9.46% respectively. Our study correlates with 
the study conducted by Reghu et alas the majority of their patients came 
under age group 20-40 years. 
b) Gender: Gender wise distribution in this study was 37 male and 37 female 
patients. Out of 37 male patients 21(28.38%) were having UC and 16(21.62%) 
were having CD. The type of UC and CD distribution in the female category 
was 15(20.27%) and 22(29.73%) respectively. Same result was obtaines in a 
study conducted by Sumant s arora which reveals that the females were 
predominance  in  CD and males were predominance in UC. 
c) Comorbid condition: In this study population (74),without any comorbidity 
condition were 39. The UC(20) and CD (19) distribution, 27.03% and 25.68% 
respectively. There were 9 IBD patients with 2 UC patients and 7 CD 
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patients,2.70% and 9.46% respectively. Among 35 UC patients 11(14.9%) 
patients were having DM  and only 3(4.1%) were having HT. 
d) Appendicitis: In this study there were only 12(16.2%) patients  having 
appendictitis and were equally having UC and CD. But some of the studies 
shows that appendectomy increased the risk of IBD. But 62 patients were not 
having appendicitis. In the study conducted by Ana  Catarinaet al result 
shows that appendectomy seems positively associated with the development of 
Crohns disease, so appendectomy should be avoided inorder to avoid the 
worsening the prognosis of IBD. 
e)  Epidemiological study: Epidemiological studies have provided compelling 
evidence that genetic factors contribute to the pathogenesis of IBD. First 
degree relatives of patients with IBD have approximately a 3 to 20 fold greater 
likelihood of developing the general population. So in this study,23,(29% of 
total population) patients were having their relatives with IBD diagnosis. In 
this study relatives of CD patients having moe than that of UC.  The same 
result was obtained by a study conducted by David kevans  there was FDR of 
CD patients having IBD than UC patients. 
f) Psychological factors: On analyzing the psychological factors like stress, 
emotion on IBD patients, patients with stress were the most than emotion.  
distribution of stress factor in 33 UC patient 44.59% and 48.65%. This 
resembles the study conducted by Jorgensen et al reported that these worries 
and stress can be regarded as a normal feature of life and cannot be related 
with the risk of developing the disease. 
g) Life style habits: Based on the lifestyle of the patients,most of them were 
taking coffee(68.9%) and 29% of patients were taking tea and most of the 
patients 62(83.8%) were non vegetarians and only 12(16.2%) were 
vegetarians. 
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II.  DISEASE CHARACTERISTICS 
a) Extra intestinal manifestation: In this study extra intestinal manifestations 
were grouped into 5 categories. There were 16  patients having arthralgia, 
among that patients with UC is 9( 9.46%), 7 patients having bache ache 
and there were only one patient having hepatobiliary and skin lesion. 
b) Disease severity: The disease severity was classified into 3 categories, 
mild, moderate and severe. Patients who diagnosedas mild condition in 11 
patients and 21 CD patients  respectively. In UC, there were 19 patients 
(25.68%) were in moderate condition and 15 (20.27%) in CD. Only 8 
patients were in severe condition .  
c) Localisation of the disease: The localization of the disease were classified 
into 4 categories in both UC and CD. The four groups in UC were 
proctitis, left colon, pan colitis and small intestine alone and in CD the 
groups were proximal, ileal, ileocolonic and colonic. Anyway 12 UC 
patients (16.22%) were having proctitis,  6 (8.11) were having left colonic 
inflammation. In 16 CD patients (22%)pancolitis 12 (16.22%)ileal 
20(27.88%) ileocolonic 8 (11.5%)colonic inflammation. 
d)  Relapse the condition: There is more chance of re occurring the disease 
again in some patients. Some of the studies shows so. In this study only 11 
patients were relapsed one.(15.6%). 
CCKNOW 
 The mean CCKNOW score during the baseline visit and the revisit period 
were 6.56±3.26 and 16.17±2.16 respectively. The mean CCKNOW scores were 
statistically significant during revisit from baseline visit(p value .000). According to 
the questions, during the  baseline visit the percentage of IBD knowledge varies from 
0% to 86 % and only less than 50% with correct answers for 18 out of 24 questions. 
The knowledge level was reassessed in the revisiting time and it ranged from  5% to 
97%, among all the questions only 9 questions  got less than 50% of correct answers. 
Among the questions, the question on elemental food showed higher percentage of 
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correct answer in the baseline visit 86% and in revisit it showed 95% in revisit. The 
question on extra intestinal manifestation shows higher percentage of correct answer. 
The question on villi  showed least percentage of correct answer in baseline visit and 
it showed only 5% in revisit. 
 In this study, we have compared demographic characteristic and the 
CCKNOW score. The results showed that, male patients have the mean CCKNOW 
score of 1.72±0.69 and female patient with the score of 1.67±0.78. This shows  Male 
patients had higher mean CCKNOW score than females patients which was 
statistically significant(p=0.039).  
 Younger age of  diagnosis was associated with higher mean CCKNOW 
scores.ie the age group 20-40years had higher mean CCKNOW score (16.79±1.70) 
compared to the age group 41-60 years(15.5±2.30) and 61-80years(16.0±2.16) with 
the statistical  analysis of (p<0.28). This is a similar result from the study conducted 
Jason k Howet al. 
 Secondary educated patients having higher mean score 16.11±2.58 than higher 
educated 15.06±1.56 and primary 16.01±0.09 educated patients showed statistically 
significant.(p>0.01). Employed patients there was higher mean score 15.76±0.0123 
than unemployed 14.76±1.1232 and students 14.23±1.56,(p>0.06). C.P Sellinger et al 
studied out that the patients with higher education shows good knowledge score. 
 Patients with ulcerative colitis(UC) had higher CCKNOW score 16.63±1.64 
compared to patient with crohns disease 15.73±2.50,(p>0.004). Duration of IBD were 
grouped into 4 sub division, in which period of >1yr had the higher mean score of 
16.25±1.70. However extra intestinal manifestation, family history, IBD related 
hospitalization were not significantly associated with CCKNOW score.  But Yang 
Sook Yoo observed  that CD patients were having more score than UC patients. 
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SIBDQ 
Comparison of SIBDQ components 
 The  SIBDQ, consisting of totally 10 questions which examines four domains: 
bowel symptoms, systemic, emotional and social functions. The comparison of 
quality of life was done before and after intervension of the patients. Each component 
shown the difference in the mean value. The components got significant difference in 
systemic domain, social domain, and in bowel domain.(p<0.05). In our study, females 
were found to be more mean score than males in every the domain. 
Association of SIBDQ with Demograhic Characters 
 The importance of HRQOL in chronic diseases has been increasingly reliable 
because of its implication on patients psychological well being and social adjustment 
to the illness. Measuring HRQoL provides important data to quantify the impact of 
the disease on the daily life of patients. The association between different domains of 
SIBDQ with demographic charecters wereanalysed and it was observed that age and 
past history had that significant relation with bowel domain(p<0.05). Also the patients 
with comorbid condition had better QoL in bowel domain(<0.05). In a study 
conducted by Azza A E et al it was reported that relapse, long duration( >5yrs), low 
education and young age at disease onset may increase the risk of patients with 
decreased HRQOL. 
Comparison of CCKNOW with SIBDQ  
 In this study,knowledge scores were compared with QoL scores before and 
after  the intervention of patient. It is found that  the mean score of knowledge was 
increased from the baseline visit. The mean score of the QoL is also increased from 
base line visit. But significantly both CCKNOW and SIBDQ has no relation. 
 Significance between scores of before intervension of knowledge and qol is 
found to be (<0.09) and after intervention it is found to be(<0.324). How JK et al also 
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done a same study on this topic and found out that the patient knowledge was not 
having any correlation with the quality of life of IBD patients. 
Patient Satisfaction  
 On patients revisit, they were provided  with a satisfaction form  inorder to get 
the feed back of the patients regarding  PSQ-18 were used and each question pointed 
by 5 point likert scale. The mean score was found to be 2.94 which can be regarded as 
the patients are neither satisfied nor unsatisfied. 
Conclusion 
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CONCLUSION 
 Disease related knowledge plays a vital  role in facilitating patient’s 
acceptance of their diagnosis and compliance with active participation  in the 
treatment of inflammatory bowel disease (IBD). In this study it was observed that 
disease related knowledge was less during the baseline visit without regular follow 
up of the patient.The result shown slight  improvement in patient knowledge with  
the post test and proper follow up was noted in patient with patient information 
leaflet in the re visit. From the study it proves that patient education programme is 
essential for better understandingabout the disease and their management in quality 
of life.  This study revealed,there is no more relationship between knowledge 
assessment and quality of life in IBD patients.  
LIMITATION OF THE STUDY 
 The main limitation of this study is duration and follow up of the patient. 
As  IBD incidence and prevalence is less and awareness about the disease is rare, 
population enrolment is minimal with short span of time and to have the 
medication adherence, long term follow up of study is mandatory. Only very few 
studies have performed by clinical pharmacist in this disease. In future we planned 
to study the patient  comprehensively from enrolment to discharge and to fill the 
gap identified in the patient by overcoming knowledge deficit regarding IBD. 
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CENTER & HOSPITAL 
INFLAMMATORY 
BOWEL DISEASE 
 
 
 
 
 
 
  
Self Help – What can you Do? 
 High calorie, high protein diet. 
 Try to have on food at right time. 
 Take vitamin and mineral 
supplements. 
 Take foods in regular interval and 
avoid large meals at a time
 
Don’t s  
 Avoid dairy products  
 Avoid caffeine 
 Avoid carbonated drinks ( beer ,wine, 
alcohol ) 
 Avoid mayonnaise , margarine 
 Avoid nuts and seeds. 
 
 Avoid junk foods and spicy foods 
 Don’t take ibuprofen and paracetamol 
 
 
 
For more Information Contact: 
 
Dr. S. ARAVINDH.MD.DM  
Consultant Gastroenterologist     
  KMCH Hospital 
(OR) 
Department of Pharmacy Practice 
KMCH College of Pharmacy,  
Phone: 04224323414 
 
  
What is inflammatory bowel disease? 
Inflammation of various regions in the GI tract. 
Its of two types 
 ULCERATIVE COLITIS (UC) 
It affects the entire large intestine, 
begins in rectum and moves upward. 
 CROHN’S DISEASE (CD) 
It affects any part from mouth to anus. 
 
CAUSES: 
 Genetics 
 
 Environmental factors 
 
 
Family history  Stress 
 
Emotions     
SIGNS AND SYMPTOMS: 
 Diarrhoea 
Constipation 
Abdominal pain 
fever 
infection 
 
Complications of IBD 
 Mouth ulcers 
 Uveitis 
 Renal stones 
 Arthritis 
How to manage IBD? 
a. Follow a low residue diet to 
relieve abdominal pain and 
diarrhea. 
b. Try to follow this treatment 
plan as closely as possible 
c. Limit dairy products 
d. Try low-fat foods 
e. Take care with fiber 
f. quitting smoking 
g. avoid stress 
h. Mild exercise can help reduce 
stress, relieve depression and 
normalize bowel function. 
i. Regular relaxation and 
breathing exercises 
 
DATA COLLECTION FORM 
 
IP/ OP. No:                                                                           DATE: 
NAME:              AGE/SEX: 
WEIGHT:                           HEIGHT: 
PRESENT COMPLAINTS: 
 
 
PAST MEDICAL HISTORY: 
 
PREVIOUS HISTORY OF SURGERY:         YES     NO 
 
APPENDICTITIS:          YES                         NO 
 
LIFE STYLE HABITS:   Coffee                        Tea       Smoking                            Alcohol 
   
FOOD HABITS:      VEG       NON-VEG 
 Fibrous 
 Non – Fibrous 
 Traditional Food 
 Junk Food 
OCCUPATION: 
FAMILY HISTORY: 
             FIRST RELATIVE    SECOND RELATIVE                      NIL 
 
PSYCHOLOGICAL FACTORS:    STRESS         EMOTION                  TRAUMA                                           
 
NEWLY DIAGNOSED:      YES                          NO   
TYPE OF IBD:  UC  CD 
 
DURATION OF IBD (months):      1-5               6-10                  >1yr 
 
IBD RELATED HOSPITALIZATION:    Nil                                   >1 
 
CLINICAL FEATURES: 
ABDOMINAL PAIN  CONSTIPATION  
MUCUS IN STOOLS  PERI ANAL DISEASE  
FEVER  ANO RECTAL PAIN  
BLOOD IN STOOLS  ANAL FISSURE  
RECTAL URGENCY  PERI ANAL FISTUAL  
CHRONIC DIARRHOEA  PEDAL EDEMA  
PALLOR  ABDOMINAL MASS  
WEIGHT LOOSE  MOUTH ULCER  
EXTRA INTESTINAL MANIFESTATIONS: 
Type of manifestation 
Arthralgia  Backache  Skin 
lesion 
 Ocular  hepatobilary  
    
LAB INVEATIGATION 
 
DATE    
TC    
ESR    
ALBUMIN    
CRP    
Hb    
 
 
  
INVESTIGATION 
COLONOSCOPY  
RETROGRADE ILEOSCOPY  
OGD  
ABDOMINAL CT  
BIOPSY  
USG  
 
DISEASE SEVERITY:      MILD         MODERATE:  SEVERE: 
LOCALISATION OF DISEASE: 
UC:          Proctitis           Left colon             Pan-colitis                   NA 
  
CD:         Proximal        Ileal           Ileo-colonic                  Colonic 
 
IBD RELAPSED PATIENT:    YES         NO 
 
COMPLICATION: 
 
 
 
 
 
 
 MANAGEMENT: 
 
DRUGS  DOSE FREQ INDICATION MODE OF 
ADMINISTRAT
ION 
V1 V2 V3 
Mesalamine        
Sulfasalazine        
Steroids        
Azathioprine        
Biologicals        
TPN        
Blood 
Transfusion 
       
Surgery        
 
Knowledge Questionnaire 
 
Diet (2 questions) 
Q1. Patients are allowed to eat dairy products 
Q2. Elemental feeds are very easy to digest.  
General IBD knowledge (11 questions) 
Q3. Proctitis is a form of colitis that affects the rectum or back passage only.  
Q4. Being symptom-free for three years does not mean IBD is cured.  
Q5. IBD runs in families. 
Q6. Inflammation can occur in other parts of the body as well as the bowel.  
Q7. A fistula is an abnormal track between two pieces of bowel or between the bowel and skin. 
Q8. The terminal ileum is a section of the bowel just before the anus 
Q9. During a flare-up of IBD, the platelet count in the blood rises 
Treatments (5 questions) 
Q10. Steroids can be given in the form of an enema into the back passage.  
Q11. Immunosuppressive drugs are given to IBD patients to reduce inflammation in the bowel. 
Q12. Sulfasalazine is used to reduce the frequency of flare-ups.  
Q13. Azathioprine is an immunosuppresive drug.  
Q14. A woman with Crohn’s disease may find it more difficult to become pregnant. 
Q15. Ulcerative colitis is common in Europeans and North Americans. 
Q16. Male patients who take sulfasalazine have reduced fertility levels that are reversible. 
Q17. The length of the small bowel is approximately 6 m.  
Q18. The function of the large bowel is to absorb water.  
Q19. Another name for an ileorectal anastomosis operation with formation of a reservoir is pouch. 
Q20. If terminal ileum is removed during surgery, the patient will have impaired absorption of vitamin 
B12. 
Q21. Patients with IBD which has lasted for 8–10 years need to be screened .for cancer of the colon. 
Q22. There are millions of tiny “hairs” in the small bowel to increase the absorptive surface, 
which are called villi. 
Q23. Headache is not a common symptom of IBD.  
Q24. A child who has IBD probably will not be as tall as his or her friends. 







































